About the Event
Kineta, Inc. (Nasdaq: KA) is a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance. With the company’s multiple programs in development and strong strategic partnerships, they are eligible for billions in milestone payments and royalties, though their market cap is currently just $25M.
Join our webinar with Kineta CEO, Shawn Iadonato to hear about the opportunities ahead for the company and what it could mean for its valuation going forward.